NCNA / NuCana: Pipeline And Major Gilead Litigation Progressing Nicely

NuCana (NASDAQ: NCNA ) stock is sliding lower on Tuesday as the clinical-stage biopharmaceutical company prepares for a presentation this week. NuCan more_horizontal

NuCana PLC Sponsored ADR (NCNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled w more_horizontal

NuCana (NASDAQ: NCNA ) stock is sliding lower on Monday after the company got an unfortunate update from the Technical Board of Appeal (TBA) of the Eu more_horizontal

NuCana's market cap is not reflecting the potential of two other drug candidates NUC-3373 and NUC-7738, currently in Phase 2 trials. The UK and EU pro more_horizontal

Regional Court of Dusseldorf has ruled in favor of NuCana plc (NASDAQ: NCNA), stating that Gilead Sciences Ireland UC and Gilead Sciences GmbH inf more_horizontal

EDINBURGH, United Kingdom, Feb. 28, 2022 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, an more_horizontal

EDINBURGH, United Kingdom, Feb. 28, 2022 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, an more_horizontal

EDINBURGH, United Kingdom, Feb. 28, 2022 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, an more_horizontal